

Cancer Vaccine Company DCPrime and Janssen To Collaborate on Potential New Therapy

Leiden, The Netherlands, October 3, 2013 – DCPrime, a Dutch clinical stage company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne[®], today announced that it has entered into a research and optional license agreement with Janssen Pharmaceuticals, Inc. The collaboration has been facilitated in conjunction with the Johnson & Johnson London Innovation Centre, where a team of business -, scientific – and transaction experts are identifying and building novel early-stage collaborations with emerging companies.

Under the agreement, Janssen will utilize DCPrime's DCOne[®] platform technology in feasibility studies for the development of a dendritic cell-based vaccine against an undisclosed solid cancer. Additionally, Janssen will have the option to further develop a therapeutic candidate towards regulatory approval.

“DCPrime is always looking for new, innovative opportunities for the application of our DCOne[®] platform technology,” said Marcel Zwaal, CEO of DCPrime. “We are very excited about having the opportunity to work with Janssen and it will enable us to further extend the application of our vaccine products.” DCPrime's founder and CSO Ada Kruisbeek said: “This is precisely the type of extension of the applicability of our platform which I envisioned when I founded the company. It will show that, beyond application of our vaccine platform in hematological cancers, also solid cancers represent targets for this treatment.”

DCPrime successfully completes their Phase I study with Dendritic Cancer Vaccine in Acute Myeloid Leukemia

Leiden, The Netherlands, May 28, 2013 DCPrime, a Dutch clinical stage company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne[®], today announced the successful completion of its Phase I/IIa study in acute myeloid leukemia (AML). The study establishes the safety and feasibility of vaccination with DCP-001, DCPrime's lead product generated from the DCOne[®] platform, in combination with clear evidence of a positive, vaccination induced immune response. Remarkably, several patients showed prolonged survival compared to historic expectations, despite the fact that these were all patients not eligible for any other treatment and a long history of disease. "Given the stage of disease of these patients, the results of our study are compelling, and provide us with a solid basis to advance our lead product DCP-001 to a multicenter Phase II study in a larger patient population and continue the development of this promising treatment for AML," say Marcel Zwaal, CEO, and Ada Kruisbeek, CSO. "We are very pleased with the encouraging results from this study," said Prof. Dr. Arjan van de Loosdrecht, principal investigator and professor of hematology at VUmc in Amsterdam. "Dendritic cell vaccines such as DCP-001 may offer AML patients a real and highly required therapeutic alternative in the near future. We look forward to working with the Company to further develop DCP-001 in a multicenter randomized Phase II trial."

About the study

The Phase I/IIa trial was an open label, non-randomized, dose escalation study that enrolled 12 patients to determine the safety and feasibility of DCP-001 in a dose-escalating schedule of 4 vaccinations with 2 weeks intervals. Patients were elderly, at high risk of relapse, and ineligible for standard post-remission therapy. DCP-001 vaccination triggered a broad, systemic T-cell and B-cell immune response. T-cell responses against specific leukemia antigens were particularly noted in patients that have prolonged survival compared to the historic expectations. Patients showed only local injection site reactions and no product related adverse events were observed. The study was conducted at the Department of Hematology of the Vrije Universiteit medical center (VUmc), Amsterdam, the Netherlands. Principal investigators were Gert Ossenkoppele, MD, PhD, professor of hematology and head of the VUmc Department of Hematology, and Arjan van de Loosdrecht, MD, PhD, professor of hematology.

About DCPrime

DCPrime is developing off-the-shelf dendritic cell-based vaccines for the treatment of a broad range of cancer types, based on its unique, proprietary technology DCOne[®] platform. Due to the endogenous expression of several defined tumor leukemia antigens (i.e. WT-1, PRAME, RHAMM, and MUC1) DCOne[®] derived vaccines deliver a strong potential for multi-targeted immunotherapy of multiple hematological malignancies, with the strong potential to become the gold standard for off-the-shelf dendritic cell-based vaccines. DCPrime has a commercial scale manufacturing process in place and is additionally developing products for treatment of solid cancers using antigen loaded DCOne[®]-based vaccines.

DCPrime awarded an Eurostars programme grant, to support the further up-scaling of its vaccine production platform

Leiden, The Netherlands, January 31, 2013 – DCPrime, a Dutch clinical stage company dedicated to developing cancer vaccines, today announced that they will join forces with EUFETS GmbH in the development of a commercial-scale production of standardized dendritic cell based cancer immuno-therapy vaccines, based on DCPrime's DCOne® platform.

This enables additional clinical investigations and future marketing of this high-potential cancer vaccine. In the Eurostars project, DCPrime and EUFETS aim at further upscaling of the DCP-001 production process. DCP-001 is DCPrime's lead product from the DCOne® platform, that was used for the Phase I/IIa study. EUFETS has extensive expertise in developing large scale cell-production processes for cellular products. Thus far, EUFETS has produced more than 1,000 products for cellular therapies and has been involved in numerous clinical trials throughout Europe. DCPrime will be able to strongly benefit from this collaboration and EUFETS' expertise in the development of its DCOne® derived products.

DCPrime awarded first SME Partnership project by TIPharma: vaccine against recurrent leukemia

Leiden, The Netherlands, October 31, 2012 – DCPrime, a Dutch clinical stage company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne®, today announced that they have been awarded an SME Partnership project from TIPharma. The project supports additional development of DCPrime's novel treatment against the recurrence of leukemia. The project will be executed in cooperation with two partners: Leiden University Medical Center (LUMC, Dept of Hematology), and Batavia Bioservices. All participating partners are located at the Bio Science Park Leiden, the Netherlands.

Batavia Bioservices will develop quantitative assay systems for monitoring stability and consistency of antigen expression in DCP-001, and the Dept of Hematology at the LUMC will develop T cell-derived tools for monitoring antigen expression in DCP-001. In most leukemia patients that receive conventional chemotherapy, the disease will reappear due to the fact that a small number of leukemic cells remains unaffected by the treatment. As a result, these cells will have the potential to grow out again, causing a relapse of the leukemia. Recently, a Phase I/IIa clinical study in patients suffering from Acute Myeloid Leukemia (AML) has been completed by DCPrime, together with the Dept of Hematology at the VUmc in Amsterdam, using DCP-001. DCP-001 is generated from DCPrime's proprietary dendritic cell (DC) technology platform DCOne®. DCP-001 is a DC based vaccine that stimulates the immune system to react against leukemia cells, because it combines DC properties with leukemia antigen expression. This new vaccine will eventually benefit large numbers of patients with leukemia, in particular in a post-remission setting.

Cancer Vaccine Company *DCPrime* appoints Marcel Zwaal CEO, and Dr. Anthony Hall CMO and expands supervisory board

October 9, 2012 – Cancer vaccine company *DCPrime* today announced the appointments of Marcel Zwaal as Chief Executive Officer, and of Dr. Anthony Hall as Chief Medical Officer. Dr. Anthony Hall has 18 years of experience in clinical drug development, in particular in orphan drug indications. Dr. Ada Kruisbeek, founder of *DCPrime* and since the start of the company active in a dual role as CEO and Chief Scientific Officer, will continue to build and expand the company's product platform technology as CSO.

"*DCPrime* is entering a new stage of its development with an on-going Phase I/IIa trial in Acute Myeloid Leukemia and a Phase II efficacy trial to start in the course of 2013," said Michel Briejer, Chairman of *DCPrime*'s Supervisory Board. "With Marcel stepping up from Chief Business Officer to the position of CEO, Ada focusing on reinforcing and expanding the platform, and Tony joining to move our clinical programs forward, *DCPrime* has a formidable team in place to bring the company's exciting new class of off-the-shelf cancer vaccines to market."

DCPrime also appointed Bart Klein to its Supervisory Board. Mr. Klein, former Executive Vice President Intellectual Property & Legal Affairs at Crucell, brings 23 years of experience in intellectual property and licensing. In addition to Mr. Klein, the Supervisory Board consists of Onno van de Stolpe, CEO of Galapagos, Dr. Herbert Heyneker, one of the most distinguished scientist entrepreneurs in the biotech industry, Dr. Leon Hooftman who, following a high-profile career in clinical development, currently is Chief Medical Officer of Synthon, and Dr. Michel Briejer, chairman and partner of Thuja Capital, *DCPrime*'s cornerstone investor.

"I am delighted to take the helm from Ada, and be given the opportunity to lead the charge to bring *DCPrime*'s cancer vaccines to patients with real unmet medical needs," said Marcel Zwaal, CEO. "Supported by our dedicated board members, our management team now has all the capabilities to make a push forward, and capitalize on our first-in-class product platform to develop effective cancer vaccines."

About *DCPrime*

DCPrime develops off-the-shelf dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne[®]. DCOne[®]-based dendritic cell vaccines, in some indications loaded with cancer antigens for targeted treatment, are used as standardized, therapeutic products. The platform combines the power of dendritic cell-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products. *DCPrime* has a commercial scale manufacturing process for DCOne[®]-based vaccines in place, and the company's lead product DCP-001 is in the clinic in a Phase I/IIa study in patients with Acute Myeloid Leukemia (AML). Several products for solid cancers are in preclinical development, using peptide loaded DCOne[®]-based vaccines.

View this news release online at:

<http://www.businesswire.com/news/home/20121008006338/en>

Equipment for the novel *DCPrime* facility at the BioPartner Centre Leiden

Leiden, The Netherlands, April 30, 2012 – *DCPrime*, a Dutch clinical stage company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform *DCOne*[®], today announced that Mibiton Solo approved an investment in their therapeutic vaccine development program.

DCPrime has developed a unique platform technology for the generation of off-the-shelf dendritic cell (DC)-based vaccines. The platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products. With the support of the BioPartner Centre Leiden, the Mibiton investment enabled *DCPrime* to equip their novel laboratory facilities at the Leiden Bio Science Park.

European Medicines Agency approves Orphan Medicinal Product application of *DCPrime's* Acute Myeloid Leukemia vaccine

Leiden, The Netherlands, February 1, 2012 – *DCPrime*, a clinical stage company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform *DCOne*[®], today announced that the Committee for Orphan Medical Products (COMP) of the European Medicines Agency has issued a positive recommendation on *DCPrime's* application for orphan drug designation of the company's dendritic cell-based cancer vaccine candidate, *DCP-001*, which targets Acute Myeloid Leukemia (AML).

Using the *DCOne*[®] platform *DCPrime* will be potentially able to generate additional off-the-shelf DC-based vaccines for a broad range of cancer types. *DCOne*[®]-based DC vaccines share all immune-stimulatory properties with patient derived DC-based vaccines, and have the simple logistics of off-the-shelf products. A commercial scale manufacturing process to produce *DCOne*[®]-based vaccines is under development, and *DCPrime's* lead product *DCP-001* is clinically tested in a Phase I/IIa study in patients with Acute Myeloid Leukemia (AML). Several products for solid cancers are in preclinical development. With this powerful platform, *DCPrime* has the opportunity to become the gold standard for off-the-shelf dendritic cell products.

DCPrime expands management team

January 1, 2012 – DCPrime is pleased to announce that Marcel Zwaal will join the company per January 1, 2012. Before joining DCPrime, Mr. Zwaal has worked for Crucell in Leiden since 2006 where he has held several senior management positions in Business Development and Corporate Finance. He has been responsible for managing Crucell's recombinant adeno vaccine development portfolio and he has concluded several collaborative financing and corporate restructuring deals. Prior to joining Crucell he has had over 10 years of experience in international finance and controlling, both as an independent consultant and in a multinational setting. Mr. Zwaal started his career at Philips Electronics. He received his EMFC degree from the Vrije Universiteit in Amsterdam.

DCPrime has been granted €1.4 million government loan for acute myeloid leukemia program

July 14, 2011 – The Dutch Ministry of Economic Affairs, Agriculture and Innovation (AgentschapNL) has decided to support DCPrime B.V. for its acute myeloid leukemia (AML) program by granting the company an “Innovation Credit” (soft loan) of €1.4 million. This covers 35% of the initial costs that are associated with the clinical development of its first candidate therapeutic cancer vaccine. DCPrime has recently started testing this innovative product in patients with AML.

The company also received an invitation by AgentschapNL to apply for additional credit for development of its second vaccine product.

“We are very pleased with this support for our AML vaccine program,” says Ada Kruisbeek, CEO and CSO of DCPrime. “There is a great need for new treatment options in patients with AML. Moreover, the studies in AML will provide more knowledge about the best use of our products.”

The company’s unique platform technology consists of sustainable dendritic progenitor cells (named “DCOne[®]”) and a proprietary method to expand these and to create functional mature dendritic cells (DCs). With this platform, DCPrime can generate vaccines against almost any cancer type.

AML was chosen as the first indication in which to test DCOne[®]-derived vaccines, because it is a disease with a high medical need, and none of the therapies currently under investigation offer high hopes. Approximately 50,000 persons worldwide are diagnosed annually with AML, and the overall 5-year survival rate with standard chemotherapy is only 26%. Clinical studies with autologous DCs have demonstrated encouraging results.

About DCOne[®] – DCOne[®] is a unique proprietary cell line which only DCPrime has access to. DCOne[®] can be used to provide a source for allogeneic functional mature DCs that can be primed with tumor associated antigens (TAA’s). As such, it can be used as a platform to generate off-the-shelf therapeutic vaccines for a broad range of cancer types. The platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products.

The company has produced GMP master and working cell banks of the DCOne[®] progenitor cells, and the first batch of GMP compliant clinical trial material has been released. DCPrime is in advanced development for establishing a scalable manufacturing process which incorporates TAA priming.

About DCPrime – DCPrime B.V. is a Dutch VC-backed biotechnology company based in Amsterdam, dedicated to developing cancer vaccines based on its proprietary dendritic cell-based cancer vaccine technology platform DCOne[®]. The company leverages this platform to

develop standardized DC-based vaccines. Since its foundation, *DCPrime* has been granted several government subsidies to develop a commercial scale manufacturing process for DCOne® derived vaccines. *DCPrime* was also supported by a seed investment of Thuja Capital in September 2010. *DCPrime's* mission is to improve healthcare of cancer patients by developing cancer vaccines as well tolerated and effective second line treatments.

About AgentschapNL and the Innovation Credit Scheme – AenstchapNL (www.agentschapnl.nl) is an agency of the Dutch Ministry of Economic Affairs, Agriculture and Innovation that promotes sustainable development and innovation with various financial instruments. The “Innovation Credit” (Innovatie Krediet) instrument is aimed at supporting high risk, and commercially attractive, development projects with an interest-bearing loan of which repayment is waived if the project fails.

DCPrime initiates its first clinical study in acute myeloid leukemia patients

April 14, 2011 – DCPrime B.V. announced today that it initiated a clinical study with its first candidate therapeutic cancer vaccine. This is a major milestone in the development of an off-the-shelf dendritic cell vaccine based on the company's proprietary DCOne® platform. The goal of the open label Phase I trial is to investigate the safety and tolerability of DCPrime's first therapeutic cancer vaccine in patients with acute myeloid leukemia (AML). The candidate vaccine will be administered to twelve AML patients whose immune responses will be closely monitored. The study will be performed at the medical center of the Vrije Universiteit, Amsterdam (VUmc), under supervision of hematology specialists Prof. Dr. Gert Ossenkoppele and Dr. Arjan van de Loosdrecht.

Ada Kruisbeek, CEO and CSO of DCPrime, said: "We are excited to have reached this important milestone in the development of this first-in-class product. An off-the-shelf cellular vaccine would be a great improvement over the autologous cellular therapies that are available today. I am grateful to all who contributed to make this happen, in particular to DCPrime's COO Dr. Sandra van Wetering, who heads the team that worked so hard to achieve this objective. We expect this study to demonstrate that a therapeutic cancer vaccine based on DCOne® is safe and well tolerated. In addition, we have designed the study in such a way that we can measure immune responses that may be indicative for potential efficacy".

About DCOne®- DCOne® is a unique cell line which only DCPrime has access to. The main advantage of the DCOne® platform is that it can be used to generate off-the-shelf dendritic cell vaccines for which a scalable manufacturing process has been developed. This platform therefore allows development of therapeutic vaccines for a broad range of cancer types. The platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products.

About DCPrime – DCPrime BV is a Dutch biotechnology company dedicated to developing cancer vaccines based on its proprietary dendritic cell-based cancer vaccine technology platform, DCOne®. The company leverages this DCOne® platform to develop standardized DC-based vaccines. DCPrime's mission is to improve healthcare of cancer patients by developing these vaccines as well tolerated and effective second line treatments.